Trajectory-based analysis of fibroblast cytoskeletal and morphological features enables automated strategies for drug screening, aging determination or tumor stratification
- 1Unit of Biophysics and Bioengineering, Department of Biomedicine, School of Medicine and Health Sciences, Universitat de Barcelona
- 2School of Engineering and Materials Science, Queen Mary University of London
Abstract
Many biological processes display a tightly-coordinated progression from an initial to a final state. Therefore, cells involved in such processes can’t be considered to exist in only two discrete phenotypes, but to be rather found within a continuum of transitional states. Here we combine fluorescence image quantification of the cytoskeleton, a high-throughput single-cell multiplex approach for cell description, with our new proposed algorithm to build trajectories, termed Phenotrax. We either construct idealized cellular trajectories using two cell populations that reflect the initial and final states of the biological phenomena studied, or quantitatively position additional cells with respect to the idealized trajectory as a means to describe them with only two simplified descriptors. In particular, we apply this strategy to two different datasets involving the activation trajectories of fibroblasts. For lung fibroblasts, we apply the approach on a screen to identify drugs that inhibit cancer-associated fibroblast activation. For breast fibroblasts, we confirm the effect of donor age on the phenotypical changes of fibroblasts. Furthermore, we show that when this dominant age-related effect is accounted for, we can also identify cancer-associated changes in fibroblasts that are linked to the tumor’s hormonal profile.
Related
- Viscous mechanical cues encode metastatic behavior through cytoskeletal-nuclear coupling and chromatin remodeling
- Antimalarial cytoskeletal targeting with broad apicomplexan activity
- miR-146b-5p Suppresses Btg2 to Promote Fibroblast Proliferation and Is Associated with Prrx2 and Myh10
- Lactate signals through hepatic fibroblast growth factor 21 to facilitate exercise-induced lipid mobilization
- Histone lactylation in fibroblast-like synoviocytes drives CXCL1-mediated immune cell recruitment in rheumatoid arthritis
BibTeX
@article{martinezblanco2026trajectorybased,
title = {{Trajectory-based analysis of fibroblast cytoskeletal and morphological features enables automated strategies for drug screening, aging determination or tumor stratification}},
author = {África Martínez-Blanco and Marta B. Ferreira and Sergio Noé and Makgyori Espinoza and Núria Gavara},
journal = {Scientific Reports},
year = {2026},
month = jul,
doi = {10.1038/s41598-026-62839-y},
url = {https://doi.org/10.1038/s41598-026-62839-y},
note = {CC BY},
}
RIS
TY - JOUR
TI - Trajectory-based analysis of fibroblast cytoskeletal and morphological features enables automated strategies for drug screening, aging determination or tumor stratification
AU - África Martínez-Blanco
AU - Marta B. Ferreira
AU - Sergio Noé
AU - Makgyori Espinoza
AU - Núria Gavara
PY - 2026
DA - 2026/07/01
JO - Scientific Reports
DO - 10.1038/s41598-026-62839-y
UR - https://doi.org/10.1038/s41598-026-62839-y
AB - Many biological processes display a tightly-coordinated progression from an initial to a final state. Therefore, cells involved in such processes can’t be considered to exist in only two discrete phenotypes, but to be rather found within a continuum of transitional states. Here we combine fluorescence image quantification of the cytoskeleton, a high-throughput single-cell multiplex approach for cell description, with our new proposed algorithm to build trajectories, termed Phenotrax. We either construct idealized cellular trajectories using two cell populations that reflect the initial and final states of the biological phenomena studied, or quantitatively position additional cells with respect to the idealized trajectory as a means to describe them with only two simplified descriptors. In particular, we apply this strategy to two different datasets involving the activation trajectories of fibroblasts. For lung fibroblasts, we apply the approach on a screen to identify drugs that inhibit cancer-associated fibroblast activation. For breast fibroblasts, we confirm the effect of donor age on the phenotypical changes of fibroblasts. Furthermore, we show that when this dominant age-related effect is accounted for, we can also identify cancer-associated changes in fibroblasts that are linked to the tumor’s hormonal profile.
SN - 2045-2322
ER -